The Future of Clinical Research in Breast Cancer
Highlights From
Trastuzumab as First-Line Therapy of Metastatic Breast Cancer
HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) as a Predictor of Response to Trastuzumab in Metastatic Breast Cancer
Docetaxel in Combination with Epirubicin as Neoadjuvant Therapy in Operable Breast Cancer
Comprehensive Review of Sentinel Lymphadenectomy in Breast Cancer
Commentary on “Comprehensive Review of Sentinel Lymphadenectomy in Breast Cancer”
Prophylactic Surgery for Women at High Risk for Breast Cancer
Commentary on “Prophylactic Surgery for Women at High Risk for Breast Cancer”
Paclitaxel, 5-Fluorouracil, and Leucovorin (TFL) in the Treatment of Metastatic Breast Cancer
Commentary on “Paclitaxel, 5-Fluorouracil, and Leucovorin (TFL) in the Treatment of Metastatic Breast Cancer”
Internet Usage Among Women with Breast Cancer
Commentary on “Internet Usage Among Women with Breast Cancer
Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients
Commentary on “Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients”
letter to the editor
The EORTC Strategy for the Early 2000's